Abstract | OBJECTIVE: To provide the clinician with an update and the current status and future direction of approved immune checkpoint inhibitors (ICIs) in oncology. DATA SOURCES: A PubMed search from January 1, 1966 to March 13, 2015 was performed using the key terms ipilimumab, pembrolizumab, lambrolizumab, nivolumab, immune checkpoint inhibitor, MDX-010, MDX-101, BMS-734016, MK-3475, SCH 900475, MDX-1106, BMS-936558, ONO-4538, CTLA-4, PD-1, or PD-L1 and cancer, oncology, or neoplasm. Additional references were identified from the investigators(') personal files, recent oncology meetings, review articles, clinical guidelines, and package inserts. STUDY SELECTION AND DATA EXTRACTION: All English-language clinical trials assessing the safety and efficacy of ipilimumab, nivolumab, and pembrolizumab in cancer were considered. The PubMed search resulted in 215 trials; 33 met inclusion criteria. A further 28 trials were identified from the above sources; 61 trials from 2005 to 2015 were included. We consolidated and clarified treatment recommendations for the management of immune-related adverse events (irAEs), assessed response criteria, and calculated the clinical utility of leading tumor profiling options. DATA SYNTHESIS: CONCLUSIONS: The treatment landscape in oncology is quickly evolving with the advent of ICIs.
|
Authors | Meagan S Barbee, Adebayo Ogunniyi, Troy Z Horvat, Thu-Oanh Dang |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 49
Issue 8
Pg. 907-37
(Aug 2015)
ISSN: 1542-6270 [Electronic] United States |
PMID | 25991832
(Publication Type: Journal Article, Review)
|
Copyright | © The Author(s) 2015. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Ipilimumab
- Nivolumab
- pembrolizumab
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Cell Cycle Checkpoints
(drug effects)
- Humans
- Ipilimumab
- Neoplasms
(drug therapy, immunology, pathology)
- Nivolumab
|